The week in pharma: action, reaction and insight – week to April 8, 2022
By Barbara Obstoj-Cardwell. Editor
Among regulatory news last week, the US Food and Drug Administration on Monday advised Alnylam Pharmaceuticals of a three-month delay to its review of the New Drug Application for amyloidosis drug vutrisiran. AstraZeneca released strong results from a Phase IIb trial of its cholesterol lowerer AZD8233. Troubled US biotech bluebird bio last Tuesday announced a significant restructuring program, which would involve a 30% reduction in its workforce. US pharma giant Pfizer announced its first M&A deal this year, agreeing a $525 million bid for RSV vaccine developer ReViral. Also, Biogen reacted angrily to the US Centers for Medicare & Medicaid Services’ (CMS) decision to limit coverage of its Alzheimer’s disease drug Aduhelm.
PDUFA delay of vutrisiran a modest headwind to guidance
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze